These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 25158954)

  • 21. Pathophysiological response to hypoxia - from the molecular mechanisms of malady to drug discovery:hypoxia-inducible factor-1 (HIF-1)-active cells as a target for cancer therapy.
    Kizaka-Kondoh S; Kuchimaru T; Kadonosono T
    J Pharmacol Sci; 2011; 115(4):440-5. PubMed ID: 21422727
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma.
    Martin SK; Diamond P; Gronthos S; Peet DJ; Zannettino AC
    Leukemia; 2011 Oct; 25(10):1533-42. PubMed ID: 21637285
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
    Gacche RN; Meshram RJ
    Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neoplasms in the bone marrow niches: disturbance of the microecosystem.
    Mu LL; Ke F; Guo XL; Cai JJ; Hong DL
    Int J Hematol; 2017 May; 105(5):558-565. PubMed ID: 28176227
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Taking advantage of tumor cell adaptations to hypoxia for developing new tumor markers and treatment strategies.
    Ebbesen P; Pettersen EO; Gorr TA; Jobst G; Williams K; Kieninger J; Wenger RH; Pastorekova S; Dubois L; Lambin P; Wouters BG; Van Den Beucken T; Supuran CT; Poellinger L; Ratcliffe P; Kanopka A; Görlach A; Gasmann M; Harris AL; Maxwell P; Scozzafava A
    J Enzyme Inhib Med Chem; 2009 Apr; 24 Suppl 1():1-39. PubMed ID: 19330638
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Angiogenesis in hematologic malignancies.
    Moehler TM; Neben K; Ho AD; Goldschmidt H
    Ann Hematol; 2001 Dec; 80(12):695-705. PubMed ID: 11797109
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic delivery of siRNA silencing HIF-1 alpha with micellar nanoparticles inhibits hypoxic tumor growth.
    Liu XQ; Xiong MH; Shu XT; Tang RZ; Wang J
    Mol Pharm; 2012 Oct; 9(10):2863-74. PubMed ID: 22924580
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hypoxia-inducible factors and hypoxic cell death in tumour physiology.
    Bacon AL; Harris AL
    Ann Med; 2004; 36(7):530-9. PubMed ID: 15513303
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Understanding the bone marrow microenvironment in hematologic malignancies: A focus on chemokine, integrin, and extracellular vesicle signaling.
    Sison EAR; Kurre P; Kim YM
    Pediatr Hematol Oncol; 2017; 34(6-7):365-378. PubMed ID: 29211600
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibiting hypoxia-inducible factor 1 for cancer therapy.
    Melillo G
    Mol Cancer Res; 2006 Sep; 4(9):601-5. PubMed ID: 16940159
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nuclear co-localization and functional interaction of COX-2 and HIF-1α characterize bone metastasis of human breast carcinoma.
    Maroni P; Matteucci E; Luzzati A; Perrucchini G; Bendinelli P; Desiderio MA
    Breast Cancer Res Treat; 2011 Sep; 129(2):433-50. PubMed ID: 21069452
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HIF expression and the role of hypoxic microenvironments within primary tumours as protective sites driving cancer stem cell renewal and metastatic progression.
    Philip B; Ito K; Moreno-Sánchez R; Ralph SJ
    Carcinogenesis; 2013 Aug; 34(8):1699-707. PubMed ID: 23740838
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of hypoxia-induced factors in tumor progression.
    Vaupel P
    Oncologist; 2004; 9 Suppl 5():10-7. PubMed ID: 15591418
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Major therapeutic advances and new perspectives in onco-hematology].
    Bay JO; Guièze R; Ravinet A; Lemal R; Xhaard A; Bailly S; Moluçon-Chabrot C; Hermet E; Biau J; Verrelle P; Peffault de Latour R; Tournilhac O
    Bull Cancer; 2013 Jun; 100(6):587-99. PubMed ID: 23735575
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic targeting of hypoxia and hypoxia-inducible factor 1 alpha in multiple myeloma.
    Borsi E; Terragna C; Brioli A; Tacchetti P; Martello M; Cavo M
    Transl Res; 2015 Jun; 165(6):641-50. PubMed ID: 25553605
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New prospects for drug development: the hedgehog pathway revealed. Focus on hematologic malignancies.
    Pimentel A; Velez M; Barahona LJ; Swords R; Lekakis L
    Future Oncol; 2013 May; 9(5):681-97. PubMed ID: 23647297
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tetraspanins set the stage for bone marrow microenvironment-induced chemoprotection in hematologic malignancies.
    Quagliano A; Gopalakrishnapillai A; Barwe SP
    Blood Adv; 2023 Aug; 7(16):4403-4413. PubMed ID: 37561544
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The extracellular matrix: A key player in the pathogenesis of hematologic malignancies.
    Sidhu I; Barwe SP; Gopalakrishnapillai A
    Blood Rev; 2021 Jul; 48():100787. PubMed ID: 33317863
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumor hypoxia in cancer therapy.
    Brown JM
    Methods Enzymol; 2007; 435():297-321. PubMed ID: 17998060
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hypoxia-inducible factor-1 (HIF-1) up-regulates adrenomedullin expression in human tumor cell lines during oxygen deprivation: a possible promotion mechanism of carcinogenesis.
    Garayoa M; Martínez A; Lee S; Pío R; An WG; Neckers L; Trepel J; Montuenga LM; Ryan H; Johnson R; Gassmann M; Cuttitta F
    Mol Endocrinol; 2000 Jun; 14(6):848-62. PubMed ID: 10847587
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.